By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT DrugSorb-ATR Submission On October 1, 2024, CytoSorbents (NASDAQ:CTSO) announced the submission of its DrugSorb-ATR medical device De Novo marketing application to the U.S. Food and Drug Administration (FDA) on September 27, 2024. The goal of this product is to reduce the severity of perioperative … Read more
By Steven Ralston, CFA NASDAQ:FMST | CSE:FAT READ THE FULL FMST RESEARCH REPORT FOREMOST ENTERS THE URANIUM INDUSTRY Foremost Enters the Uranium Exploration Industry Through an Option Agreement with Denison On September 24, 2024, Foremost Lithium (NASDAQ:FMST) (CSE:FAT) announced the signing of an Option Agreement with Denison Mines Corp. (NYSE:DNN (TSX:DML) concerning 10 Uranium Exploration … Read more
By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a scientific stage firm that’s making AI helpful within the present surroundings through the use of the know-how to develop new cancer-fighting vaccines. The corporate notes that it has demonstrated that it could determine, via the corporate’s AI fashions, novel targets … Read more
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Enterprise Replace Mpox Declared a. Public Well being Emergency of Worldwide Concern On August 14, 2024, the World Well being Group (WHO) declared mpox a public well being emergency of worldwide concern. The present outbreak of mpox was brought on by Clade 1 monkeypox … Read more
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs On September 2, 2024, Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) introduced outcomes for the Part 3 PALISADE trial of plozasiran in sufferers with familial chylomicronemia syndrome (FCS). The outcomes had been … Read more
